Phathom Pharmaceuticals (PHAT)
(Delayed Data from NSDQ)
$12.21 USD
+0.39 (3.30%)
Updated Oct 3, 2025 04:00 PM ET
After-Market: $12.30 +0.09 (0.74%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PHAT 12.21 +0.39(3.30%)
Will PHAT be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for PHAT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PHAT
Phathom Pharmaceuticals (PHAT) Upgraded to Buy: Here's Why
Wall Street Analysts See a 66.13% Upside in Phathom Pharmaceuticals (PHAT): Can the Stock Really Move This High?
PHAT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Think Phathom Pharmaceuticals (PHAT) Could Surge 87.21%: Read This Before Placing a Bet
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue Estimates
MannKind (MNKD) Reports Break-Even Earnings for Q2
Other News for PHAT
NR7 appears for PHAT after 3.3% move
Is PHAT signaling a buying opportunity? 20 Day Moving Average Support shows up after declining 3.82%
Is PHAT primed for upward momentum? Crossed Above 20 Day Moving Average shows up after advancing 4.42%
PHAT forms Pocket Pivot on September 30
12 Health Care Stocks Moving In Wednesday's After-Market Session